DARWIN EU® - Chondrosarcoma: patient demographics, treatments, and survival in the period 2010-2023

Study type

• Study topic:
  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Disease epidemiology
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Medical condition to be studied:
  Chondrosarcoma

Population studied

• Short description of the study population:
  The study population will include all individuals with a first diagnosis of chondrosarcoma identified in each database between 01/01/2010 and 31/12/2023. Participants with a diagnosis of cancer (any, excluding non-melanoma skin cancer) or enchondroma before the diagnosis of chondrosarcoma will be excluded.
• Age groups:
  All

  Paediatric Population (< 18 years)

  Preterm newborn infants (0 – 27 days)

  Term newborn infants (0 – 27 days)

  Children (2 to < 12 years)

  Adolescents (12 to < 18 years)

  Adult and elderly population (≥18 years)

  Adults (18 to < 65 years)

  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Elderly (≥ 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)

Study design details

• Study design:
  A retrospective cohort study of all newly diagnosed chondrosarcoma cases will be conducted.
• Main study objective:
  To describe demographics, treatments, and overall survival of patients with incident chondrosarcoma, stratified by age, sex, study period, country/database, and, if available, by AJCC/UICC TNM stage categories and histological grade in 2010-2023.; The specific objectives of this study are:; 1. To describe demographic characteristics (age and sex) of patients with chondrosarcoma at the time of diagnosis.; 2. To describe chondrosarcoma treatment with medicines (chemotherapy and biologics) in patients that had undergone or not surgery, radiotherapy, both or neither. ; 3. To estimate the overall survival of newly diagnosed chondrosarcoma patients during the study period (2010-2023).;
• Setting:
  This study will use routinely collected health data from 6 nationwide and region-wide databases in 5 European countries.

Documents

Study report

DARWIN EU_Report_P3-C1-003_Chondrosarcoma_V2.pdf